Glen Travers: Empowering Millions with Next-Gen Diabetes Care

You are currently viewing Glen Travers: Empowering Millions with Next-Gen Diabetes Care
Glen Travers

Innovation is the engine that drives progress, yet it requires an exceptional leader to effectively harness it and address the most significant global issues facing us today. Glen Travers is one of these rare individuals. To him, innovation goes beyond merely developing something new; it focuses on addressing significant issues that impact individuals in their everyday lives. As the Co-founder of Diabetology Ltd, Glen has spent years reforming the way we approach healthcare, especially diabetes. However, it’s not just about developing a product, it’s about rethinking what’s possible and delivering solutions that can make a meaningful difference in the lives of millions.

Diabetology Ltd, under Glen’s guidance is leading the biotech field with the creation of an oral insulin delivery system that has the potential to transform the treatment of diabetes. By dealing with the drawbacks of traditional insulin injections, Glen’s advanced method aims to simplify, enhance safety, and improve the effectiveness of diabetes management for Type 1 and Type 2 patients globally. By using advanced technology and a strong dedication to enhancing patient results, the company is redefining the possibilities of biotechnology.

For Glen, innovation holds a personal significance. His path, which started with initial achievements in finance before transitioning to medical technologies, showcases his commitment to addressing practical issues. Collaborating with his exceptional scientific co-founder, Dr. Roger New, Glen has transformed Diabetology Ltd into a company that is both innovating in diabetes treatment and setting the stage for future advancements in various medical fields. His dedication to discovering innovative solutions distinguishes him as a genuine leader in the biotech sector.

Let’s learn about the pioneering efforts behind the world’s first oral insulin solution!

A Journey of Early Success

Glen’s story is not one of overnight success but of a career shaped by a series of calculated risks, a deep curiosity for medical science, and an innate drive to improve the world around him. His initial foray into the world of business came when he co-founded an equity bank. The venture was a success, and it gave him the financial means and resources to branch into a field that had fascinated him for years: life science and medical technology.

Looking back on those early years, he reflects on a partnership that would ultimately set the stage for his future endeavors. His equity bank was involved in a variety of novel medical projects, one of the most notable being a collaboration involving an observation by what were to become two Nobel Prize-winners. They worked on eradicating Helicobacter pylori in patients with gastric ulcers. This work didn’t just result in a medical breakthrough—it led to the development of the first point-of-care diagnostic for an infectious disease, which was later licensed to multinationals. The impact of this success was immense, as once the bacteria’s presence could be rapidly identified at point of care, the disease could be ‘cured’ with a simple 3 week combination eradication therapy. This also taught him invaluable lessons about the challenges and complexities of turning scientific advancements into practical, life-changing solutions.

It was this experience that solidified his decision to fully dedicate his career to tackling the most pressing health challenges. The realization that he could contribute to solving complex medical issues led him to his next major achievement: developing the first-ever oral therapeutic vaccine for chronic bronchitis, which was ultimately sold to a major multinational. These early successes laid the foundation for his future work in diabetes and obesity care.

The Diabetes Breakthrough

As Glen and Dr. New worked through these early ventures, they quickly saw an urgent need in the biotechnology industry: a solution to the challenges faced by diabetics. At the time, recombinant technology had revolutionized the industry by allowing the manufacture of proteins and peptides, including insulin. However, one glaring issue remained: insulin had to be injected, a process that was not only inconvenient but often resulted in off-target effects. For him, this was a clear gap in the market.

“We believed that insulin injections were suboptimal,” he explains. “There had to be a better way. We saw the potential for an oral insulin formulation that could target the liver directly, avoiding the risks of hypoglycemia and hyperglycemia and potentially impacting disease effects like blindness, neuropathy, and certain cancers.”

With a deep understanding of both the scientific and business sides of medical breakthroughs, Glen and his team set their sights on the impossible: an oral insulin system that could replicate the body’s natural insulin delivery mechanism. The challenge was enormous. No one had succeeded in this area, and the industry consensus was that it couldn’t be done. But for him, it was a challenge worth taking on.

The Birth of an Innovative Solution

This vision led to the formation of Diabetology Ltd, where Glen, alongside Dr. New, began developing what would become a groundbreaking delivery system. Their mission was simple but audacious: to develop a safe oral insulin capsule formulation that could be absorbed in the upper intestine and transported via the portal vein to the liver. By using the body’s own natural pathways, they aimed to revolutionize diabetes treatment, ensuring that insulin could be delivered effectively without the need for painful injections or the unwanted side effects associated with injected insulin.

The road to success, however, was not easy. There were many who told them their vision was impossible. But each rejection only made Glen more determined. With the support of visionary partners and the expertise of his co-founder, they began solving the complex challenges involved in oral insulin delivery. Their first breakthrough came when they developed Axcess, a safe and effective formulation designed to overcome the barriers to successful delivery of macromolecules like recombinant human insulin. After years of work and testing, their results were published in leading peer-reviewed journals, confirming the efficacy and safety of the formulation.

What makes this achievement all the more remarkable is that they achieved it without relying on large-scale funding from traditional pharmaceutical companies. In an industry where many breakthroughs have failed due to lack of financial backing, Glen and Dr. New were able to privately finance the initiative from discovery through to clinical trials. This self-sustained model was critical to their success and enabled them to prove that their vision could be realized cost-effectively.

Tackling Metabolic Diseases

But their work didn’t stop at insulin. As Glen and his team looked at the broader implications of their technology, they realized that the same delivery system could be used for other vital treatments. One of the next frontiers was GLP-1 receptor agonists, which are used in the treatment of both diabetes and obesity. His innovative delivery system allowed these drugs to be safely absorbed through the gut, where they could trigger satiety responses and improve glucose control, without the side effects often seen with injectable drugs.

“By delivering GLP-1 treatments directly to the gut, where they can be processed naturally, we hope to avoid the off-target effects that come with injected treatments,” he explains. This approach not only improved the efficacy of treatments for diabetes and obesity but also opened the door to new possibilities for other chronic conditions.

What makes this delivery system even more revolutionary is that it targets the gut, where key hormones are naturally produced. The gut’s role in regulating metabolism has been well-documented but leveraging that natural process to improve the body’s response to diabetes and obesity treatment is an entirely new approach. Glen’s work has not only advanced the science of drug delivery but also deepened our understanding of how the body can be harnessed to improve health outcomes.

Pushing Beyond the Impossible

Throughout his career, Glen has faced a wide range of challenges, but the biggest obstacles have often been rooted in skepticism. The biotech industry is notorious for its cautious approach, and many of the breakthroughs he and his team pursued were initially met with doubt. The idea that stomach ulcers were caused by bacteria, the concept of using oral vaccines to treat chronic bronchitis in the lung, and the notion that insulin could be delivered orally—all of these were once considered impossible. Yet, time and again, he proved the doubters wrong by generating data, pushing forward with innovative testing, and building relationships with visionary supporters who believed in his mission.

“Our greatest achievements came not just from innovation, but from the persistence to challenge established dogma and to prove that there’s always room for new solutions,” he says. And it was through this perseverance that Glen managed to build a company capable of achieving the impossible.

It was this drive and determination to challenge the status quo that enabled Glen to carve out a unique place for Diabetology Ltd in the biotech space. By refusing to accept limitations, he has transformed the company into one of the most influential players in the field today.

A Collaborative Leadership Style

Glen’s approach to leadership reflects his belief in the power of collaboration. Early on, he adopted a strategy that was both directional and collaborative, ensuring that every team member, partner, and outsourced expert felt invested in the mission. “We were attempting the impossible, and that motivated people to join us. They wanted to be part of something that was bigger than just a company—they wanted to be part of changing the world,” he reflects.

His leadership style has fostered a company culture that thrives on relationships and shared vision. The partnership with Dr. New is a prime example of this, as their complementary skills have been the foundation for Diabetology’s success. His ability to build and maintain strong relationships, both within the company and with external collaborators, has been key to navigating the complex world of biotechnology.

A Vision for the Future

Looking ahead, Glen sees an exciting future for Diabetology Ltd, one where targeted molecular delivery systems could not only revolutionize the treatment of diabetes but also other chronic conditions. He envisions a world where treatments are more personalized, more effective, and less invasive. “We aim to help the global population access better treatments through our delivery systems, whether that’s for diabetes, obesity, or other health challenges,” he says.

The future is bright for those with diabetes, as Glen and his team work to develop solutions that can reverse the early stages of Type 2 diabetes and reduce the risks of hypoglycemia and hyperglycemia for Type 1 diabetics. Moreover, their work with oral GLP-1 formulations has the potential to shift how the industry approaches weight management and metabolic health. His vision is clear: to create a world where diabetes is no longer a barrier to living a full, healthy life.

The ultimate goal? To not only create groundbreaking treatments but to fundamentally change how we think about healthcare, and to ensure that patients are no longer bound by the limitations of outdated medical practices. With his leadership and vision, Glen is paving the way for a future where biotechnology is at the leading edge of solving some of the world’s most challenging health issues.